PubMed Journals Articles About "Late John Mendlein Joins Reinventing Biotech Lineup April" RSS

01:26 EDT 25th May 2015 | BioPortfolio

Late John Mendlein Joins Reinventing Biotech Lineup April PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Late John Mendlein Joins Reinventing Biotech Lineup April articles that have been published worldwide.

More Information about "Late John Mendlein Joins Reinventing Biotech Lineup April" on BioPortfolio

We have published hundreds of Late John Mendlein Joins Reinventing Biotech Lineup April news stories on BioPortfolio along with dozens of Late John Mendlein Joins Reinventing Biotech Lineup April Clinical Trials and PubMed Articles about Late John Mendlein Joins Reinventing Biotech Lineup April for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Late John Mendlein Joins Reinventing Biotech Lineup April Companies in our database. You can also find out about relevant Late John Mendlein Joins Reinventing Biotech Lineup April Drugs and Medications on this site too.

Showing "Late John Mendlein Joins Reinventing Biotech Lineup April" PubMed Articles 1–25 of 3,400+

Extremely Relevant

Biotech drugs too little, too late for Ebola outbreak.

Relevant

Reinventing tech transfer.

Reinventing neutron science in Europe.

Erratum: Reinventing tech transfer.

Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL.

Current HIV-1 vaccines based on the HIV-1 envelope glycoprotein spike (Env), the only relevant target for broadly neutralizing antibodies, are unable to induce protective immunity. Env immunogenicity can be enhanced by fusion to costimulatory molecules involved in B cell activation, such as APRIL and CD40L. Here, we found that Env-APRIL signaled through the two receptors, BCMA and TACI. In rabbits, Env-APRIL induced significantly higher antibody responses against Env compared to unconjugated Env, while the ...

2016 Call for Conference Proposals What Is the Purpose of Health Promotion? Money, Health, or More? Do We Need to Produce a Huge ROI, or Do We Need to Engage People, Improve Health and Better Serve the Organization or Community's Broader Goals?26th Annual Art & Science of Health Promotion Conference, April 25-April 29, 2016 | Hilton Orlando Lake Buena Vista | Orlando, FloridaCore Conference: April

Pfizer joins PD-L1 pursuit.

Third-quarter biotech job picture.

Biotech on the bounce in 3Q14.

First-quarter biotech job picture.

Warren joins lawmakers proposing new ideas for science funding.

Identification of the sAPRIL Binding Peptide and Its Growth Inhibition Effects in the Colorectal Cancer Cells.

A proliferation-inducing ligand (APRIL) is a member of the tumor necrosis factor (TNF) super family. It binds to its specific receptors and is involved in multiple processes during tumorigenesis and tumor cells proliferation. High levels of APRIL expression are closely correlated to the growth, metastasis, and 5-FU drug resistance of colorectal cancer. The aim of this study was to identify a specific APRIL binding peptide (BP) able to block APRIL activity that could be used as a potential treatment for colo...

Public biotech 2013-the numbers.

Benchmarking biotech and pharmaceutical product development.

Erratum: University biotech patenting 2013.

Fourth-quarter biotech job picture.

Fresh from the biotech pipeline-2014.

2014-the biotech bull rages on.

Biotech continues to soar in 1Q15.

NewsCAP: Nebraska joins 19 other states in granting full practice authority to NPs.

Erratum: Public biotech 2013-the numbers.

Big-cap buying bonanza trickles down to small biotech.

Improving biotech education through gamified laboratory simulations.

Small biotech steers HDAC inhibitor to clinic.

CRISPR germline editing reverberates through biotech industry.


Search BioPortfolio:
Loading
Advertisement
Advertisement

PubMed Database Quicklinks